Register now for FREE limitless entry to Reuters.com
- Firm eyes 13-17 billion euros in 2022 Comirnaty gross sales
- Estimate for 2021 gross sales is 16-17 bln eur
- Sees “historic likelihood” to reinvest in firm’s progress
FRANKFURT, Jan 11 (Reuters) – BioNTech stated it might seemingly generate as much as 17 billion euros ($19 billion) in 2022 income from the COVID-19 vaccine it co-developed with Pfizer , pledging to spend earnings on improvement of most cancers medication and new vaccines.
In presentation slides for J.P. Morgan’s annual healthcare convention, which is being held just about this 12 months, the German biotech agency stated on Tuesday it expects 13 billion to 17 billion euros in income accruing to it from the vaccine this 12 months, which compares with a steering of 16 billion-17 billion euros for 2021.
The monetary windfall from the Comirnaty shot, its first product available on the market for the reason that firm’s 2008 inception, presents a “historic likelihood to speed up our imaginative and prescient by way of reinvestment within the firm”, it stated within the slides.
Inspired by the earnings prospects, BioNTech has accelerated scientific testing on people of assorted product candidates, by far the most costly section of growing new medicines.
In accordance with the presentation, it began 5 scientific trials final 12 months with experimental oncology medication beforehand not examined on people and moved two trials into the second section of testing on people. Three phases are usually wanted for market approval although in oncology regulators are more and more contemplating clearance even after the second section.
BioNTech has an influenza vaccine within the first section of testing on people and plans to begin human testing of 4 vaccine candidates towards shingles, malaria, tuberculosis and herpes simplex this 12 months.
In one other signal of fast progress, the headcount in analysis and improvement elevated by 40% final 12 months to greater than 850 employees.
($1 = 0.8824 euros)
Reporting by Ludwig Burger; Enhancing by Emelia Sithole-Matarise